22 news items
Akero Therapeutics, Inc. Investors Reminder: A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. (AKRO) - Contact Kessler Topaz Meltzer & Check, LLP
AKRO
9 Jun 24
recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers
AKRO: Akero Therapeutics, Inc. Investors Reminder: A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. - Contact Kessler Topaz Meltzer & Check, LLP
AKRO
5 Jun 24
recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors
Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc.
AKRO
4 Jun 24
of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers
Class Action Announcement for Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc.
AKRO
1 Jun 24
billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Akero Therapeutics, Inc. (AKRO)
AKRO
31 May 24
for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal
skyjr9v6go468z gs5u92tif
AKRO
29 May 24
billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers
xyxqjq6zod9d r18pakpnktkfu590zxt9j08jn6ykaq5on581pexp1zhx
AKRO
28 May 24
as a viable NASH treatment. The truth came to light in Oct. 2023 when Akero announced the SYMMETRY trial failed to meet its primary goal
u43n6rtd
AKRO
23 May 24
as a viable NASH treatment. The truth came to light in Oct. 2023 when Akero announced the SYMMETRY trial failed to meet its primary goal
ut2uinl1pce3xwv143hnn7xfll3ciu
AKRO
23 May 24
of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses
iekfsgnhgms2
AKRO
22 May 24
of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect
36tz wtrwsdpk81yebws0kw3p54idtlx0e4rk1jynno5448ol9awd
AKRO
20 May 24
trial failed to meet its primary goal. Additionally, they disclosed the exclusion of data from patients with cryptogenic cirrhosis, triggering
hkj9 3szmyhohqvoyqbdxn
AKRO
19 May 24
of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors
i05d9i njap649l77xajc493tx601k490dgmmzg2udqzuy4b787ufkid
AKRO
17 May 24
misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence
3k3s6b9t
AKRO
16 May 24
of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors
1ajrclrqk6ccwjaakpj6f9l3xhzur3swz02s6gsgjz9vrthl
AKRO
16 May 24
as a viable NASH treatment. The truth came to light in Oct. 2023 when Akero announced the SYMMETRY trial failed to meet its primary goal
xj14pu9fe9xcs9ekwuyvb1fq0vq
AKRO
13 May 24
announced the results of the EFX Phase 2b SYMMETRY trial. This revealed that the trial did not meet its primary goal. During a call with investors
t294bnvn1lml7h9qbl9uax3n
AKRO
13 May 24
as a viable NASH treatment. The truth came to light in Oct. 2023 when Akero announced the SYMMETRY trial failed to meet its primary goal. Additionally
jgp1je7r782pnliob1ujgbjpo19y1f39j9w2g3q qjy5n0
AKRO
11 May 24
for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from
jg7ipphicslj16q690m04 mkuzbtv
AKRO
10 May 24
of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors
l33vlpj802xa auddss2xtw
AKRO
5 May 24
for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from